At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
TAK-272drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating TAK-272 for Renal Impairment and Hepatic Impairment. Completed, enrolled 48 participants across 4 sites.
Detailed Summary
The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment, Hepatic Impairment
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedFeb 20, 2015
Enrollment StartMar 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.4 years ago
Interventions
TAK-272drug
TAK-272 tablet